One cancer, one patient, one vaccine

With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies.
The treatment is based on an optimized MVA viral vector.

myvac® video

Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens) selected by NEC’s AI.

Once injected into the patient, this therapeutic vaccine will stimulate the patient’s immune defenses to allow the targeted destruction of cancer cells.

To carry out this project, Transgene relies on a unique expertise, a network of prestigious and recognized partners at every stage of product development and integrated manufacturing capabilities.